Clinical trials: Immunoglobulin E-Mediated Allergic Disorder
- Condition Immunoglobulin E-Mediated Allergic Disorder
- Funder type Industry (pharma, biotech, devices)
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals
Food Allergy
Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
This is an expanded access program of dupilumab. The objective of the program is to provide continued dupilumab to adult participants with severe IgE-mediated food allergy who were previously treated with a short course of…
- Trial name
- NCT06631677
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Type I Hypersensitivity
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen.
- Trial name
- NCT00104377
- Testing
- Grass MATA MPL
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy
Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever).
- Trial name
- NCT00110786
- Testing
- Ragweed MATAMPL
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of the modified ragweed pollen in Ragweed MATA MPL (modified pollen allergen tyrosine adsorbate + Monophosphoryl Lipid A) by skin prick testing.
- Trial name
- NCT00116285
- Testing
- Ragweed MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Type I Hypersensitivity
Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis
Tree MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to Tree (birch, alder, hazel) pollen (hay fever).
- Trial name
- NCT00387478
- Testing
- Tree MATA MPL or Tree MATA
- Where
- Canada
- Volunteers
- 121 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Tree MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00107705
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Grass MATA MPL
Grass MATA MPL has been developed by Allergy Therapeutics (UK) Ltd. to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass pollens causing rhinitis and/or…
- Trial name
- NCT00414141
- Testing
- Grass MATA MPL
- Where
- 94 sites in United States, Austria and 2 more
- Volunteers
- 1,028 people
- Sponsor
- Allergy Therapeutics
Cow's Milk Allergy
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
The aim of this interventional study is to assess the hypoallergenicity of a new formula in infants having a cow milk allergy (CMA), whatever the type of CMA, meaning in both IgE-mediated and non-IgE-mediated CMA patients.
- Trial name
- MERLIN (NCT06481280)
- Testing
- Test Formula
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 70 people
- Sponsor
- United Pharmaceuticals
Type I Hypersensitivity
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever).
- Trial name
- NCT00325338
- Testing
- Ragweed MATAMPL
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Ragweed MATA MPL
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis…
- Trial name
- NCT00423787
- Testing
- Ragweed MATA MPL
- Where
- 76 sites in United States, Canada
- Volunteers
- 993 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00133159
- Testing
- Grass MATAMPL
- Where
- 3 sites in Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Allergy to House Dust, Allergy Pollen
Validation and Reproducibility of S.P.A.T. With Allergens
To improve accuracy and take out human error opportunities, Hippo Dx developed S.P.A.T., an automated skin prick test. This study will provide a comparison between manual and automated skin prick test in allergic and non-allergic…
- Trial name
- NCT05824637
- Testing
- Skin Prick Automated Test, Skin Prick Manual Test
- Where
- Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Hippocreates
Type I Hypersensitivity
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
The purpose of this study is to assess the immunological differences between three RagweedMATAMPL treatment arms compared to placebo with respect to immunoglobulin levels.
- Trial name
- NCT00258635
- Testing
- RagweedMATAMPL
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00104390
- Testing
- Grass MATA MPL
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00133146
- Testing
- Grass MATA MPL
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Allergy Therapeutics
Atopic Immunoglobulin E-Mediated Allergic Disorder
A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
The primary objective of this study is to assess the safety and tolerability of STMC-103H compared to placebo in allergic subjects who are otherwise healthy.
- Trial name
- NCT03819881
- Testing
- STMC-103H
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.
Cow Milk Allergy
Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins
The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in…
- Trial name
- NCT03557671
- Testing
- rice formula
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 72 people
- Sponsor
- United Pharmaceuticals